Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up
- Sponsor
- Centre Paul Strauss
- Study ID
- NCT07628257
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences — OTHERfluorodeoxyglucose (Fluor18) (18F-FDG) PET/MRI with additional DTI and rs-fMRI sequences correlation with neuropsychological tests
Study Details
The aim of this study is to determine whether the diffuse cerebral metabolic disturbances observed in glioblastoma are exclusively linked to the direct and indirect effects of tumor infiltration (particularly structural disconnection), or whether they also reflect a more global alteration of neurometabolic and neurovascular coupling mechanisms. This approach thus aims to better understand the pathophysiological basis of cognitive impairment in glioblastoma and to characterize the impact of the disease at the level of brain networks.
Key Dates
- First listed
- Jun 4, 2026
- Start date
- Sep 15, 2026
- Status verified
- Jun 2026
- Primary completion
- Sep 15, 2030
- Completion
- Sep 15, 2030
Study Design
- Enrollment
- 80 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Other: Patients with glioblastoma treated in the Department of Nuclear Medicine & Molecular Imaging
Primary Outcome Measure
Correlation between cortical energy activity (FDG PET), axonal morphological connectivity (DTI - MRI), synchronous neuronal activity (rs-fMRI), and preoperative neuropsychological performance before surgery [ Time Frame: Before surgery ]
Central Contacts
- Claire VIT(0)388258529
- Manon VOEGELIN(0)368339523
Find similar trials
Related Studies
- Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOAPHASE2 · Recruiting · Northwell Health · New York, New York
- Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed GlioblastomaPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)PHASE2 · Recruiting · Patrick Wen, MD · Boston, Massachusetts
- Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBMPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York